Granules India Ltd (GRANULES) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 532482 | NSE: GRANULES | Pharmaceuticals & Drugs | Small Cap

Granules India Share Price

560.30 -6.25 -1.10%
as on 05-Dec'25 09:52

Granules India Ltd (GRANULES) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 532482 | NSE: GRANULES | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Granules India

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Granules India stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
36.73
Market Cap:
13,748.4 Cr.
52-wk low:
412.1
52-wk high:
621.1

Is Granules India Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Granules India: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Granules India Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 20.4%16.8%12.7%11.6%22.7%26.5%16.3%19.6%17.1%11.7%-
Value Creation
Index
0.50.2-0.1-0.20.61.00.20.50.3-0.1-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 1,3281,3491,6472,0982,3103,1353,2383,9313,7553,0303,243
Sales YoY Gr.-1.6%22%27.4%10.1%35.7%3.3%21.4%-4.5%-19.3%-
Adj EPS 5.66.45.3612.722.615.920.918.112.315.4
YoY Gr.-14.7%-17.1%13.4%111%77.9%-29.5%31.1%-13.1%-31.9%-
BVPS (₹) 29.338.650.155.770.986.9101.6111127.8139.7146.2
Adj Net
Profit
121146135153322559394505439299374
Cash Flow from Ops. 14419024227495375280664317823-
Debt/CF from Ops. 4.53.540.84.41.82.23.71.43.31-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 9.6%5.6%-2.2%-19.3%
Adj EPS 9.2%-0.6%-8.1%-31.9%
BVPS18.9%14.5%11.2%9.4%
Share Price 13.8% 5.9% 18% -1.2%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
22.118.912.411.319.928.116.819.315.19.210.8
Op. Profit
Mgn %
20.322.317.815.921.427.820.221.521.518.719.7
Net Profit
Mgn %
9.110.88.27.31417.812.212.811.79.911.5
Debt to
Equity
10.70.80.70.50.40.40.30.30.20
Working Cap
Days
168241278237195169211198227276128
Cash Conv.
Cycle
7811511711498741109511715534

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Granules India Ltd.

Standalone Consolidated
TTM EPS (₹) 15.4 21.1
TTM Sales (₹ Cr.) 3,243 4,834
BVPS (₹.) 146.2 164.1
Reserves (₹ Cr.) 3,524 3,959
P/BV 3.87 3.45
PE 36.73 26.81
From the Market
52 Week Low / High (₹) 412.05 / 621.10
All Time Low / High (₹) 1.57 / 724.55
Market Cap (₹ Cr.) 13,748
Equity (₹ Cr.) 24.3
Face Value (₹) 1
Industry PE 40.7

Management X-Ray of Granules India:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *4.034.034.034.030.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Granules India - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Granules India

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales1,3281,3491,6472,0982,3103,1353,2383,9313,7553,030
Operating Expenses 1,0581,0541,3531,7661,8162,2742,5943,0962,9542,465
Manufacturing Costs99122152173195233291294364403
Material Costs7306599031,2501,2221,5101,7582,1611,9071,344
Employee Cost 106126148167193234248278333342
Other Costs 123148150175206296298362350376
Operating Profit 270296294332494861644835801565
Operating Profit Margin (%) 20.3%21.9%17.8%15.8%21.4%27.5%19.9%21.2%21.3%18.6%
Other Income 715242826141813641
Interest 37323328272416397263
Depreciation 58717691102118126146144146
Exceptional Items 0000161000031
Profit Before Tax 181207208242553733520664591427
Tax 60646980109180133165155108
Profit After Tax 121143139162444553387499436319
PAT Margin (%) 9.1%10.6%8.5%7.7%19.2%17.6%11.9%12.7%11.6%10.5%
Adjusted EPS (₹)5.66.35.56.417.522.315.620.618.013.2
Dividend Payout Ratio (%)12%14%18%16%6%7%10%7%8%11%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 6368821,2731,4161,8032,1522,5182,6863,0973,389
Share Capital 22232525252525242424
Reserves 6148591,2471,3911,7772,1282,4942,6623,0733,365
Minority Interest0000000000
Debt577598958933793743954812954756
Long Term Debt184124433479421334234149500
Short Term Debt393474525454372409720663904756
Trade Payables177210261277323508607744655613
Others Liabilities 178165147198228280294261300393
Total Liabilities 1,5681,8552,6392,8243,1463,6834,3734,5035,0065,152

Fixed Assets

Gross Block7859371,0661,1951,5231,6931,9492,2012,3122,499
Accumulated Depreciation2613324054955967087788719891,094
Net Fixed Assets 5236066607009279851,1711,3301,3241,405
CWIP 351322863331301642116353121
Investments 8975755064455925976779411,282
Inventories210238227314344462591593579648
Trade Receivables4444686937046271,0141,2101,3721,6331,295
Cash Equivalents 111399762272241355203228170
Others Assets 155297600204401225238265248231
Total Assets 1,5681,8552,6392,8243,1463,6834,3734,5035,0065,152

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 14419024227495375280664317823
PBT 181207208242553733520664591427
Adjustment 919592122-54154137178229229
Changes in Working Capital -80-53-223-50115-326-234-1-347257
Tax Paid -48-59-53-87-120-186-143-177-157-91
Cash Flow From Investing Activity -171-300-495-243-165-233-318-96-303-552
Capex -100-184-275-188-119-222-324-212-119-205
Net Investments 0-1-0220-14020016-13
Others -72-115-220-57-6635-84-200-335
Cash Flow From Financing Activity 8636529-17-212-296151-51926-340
Net Proceeds from Shares 106832931043335
Net Proceeds from Borrowing -55-66250102-60-102-95-93-102-100
Interest Paid -37-32-31-28-27-24-17-37-72-57
Dividend Paid -23-22-29-31-31-25-37-19-36-36
Others 967346-62-95-150298-374233-152
Net Cash Flow 58-7358-33118-1541134840-70

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)22.818.8212.9212.0427.5927.9516.5519.1715.089.85
ROCE (%)20.3616.7912.7111.5622.6726.5316.2919.5517.0611.7
Asset Turnover Ratio1.010.80.740.770.780.930.80.890.790.6
PAT to CFO Conversion(x)1.191.330.171.41.110.680.721.330.732.58
Working Capital Days
Receivable Days8612112812010594125120146175
Inventory Days53595147524659555773
Payable Days90107957890100116114134172

Granules India Ltd Stock News

Granules India Ltd FAQs

The current trading price of Granules India on 05-Dec-2025 09:52 is ₹560.3.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Granules India stood at ₹13,748.4.
The latest P/E ratio of Granules India as of 04-Dec-2025 is 36.73.
The latest P/B ratio of Granules India as of 04-Dec-2025 is 3.87.
The 52-week high of Granules India is ₹621.1 and the 52-week low is ₹412.1.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Granules India is ₹3,243 ( Cr.) .

About Granules India Ltd

Granules India Limited is a large-scale vertically integrated Company founded in 1991 manufacturing Active Pharmaceutical Ingredient (API), Pharmaceutical Formulation Intermediate (PFI) and Finished Dosage (FD). The Company over the years has created a strong presence in ‘the first line of defence’ products such as Paracetamol, Ibuprofen, Metformin, Methocarbamol, and Guaifenesin.

The company’s product-focused, vertically integrated business model has created a leadership position in several generic drugs. It has a strong presence in ‘first line of defence’ products, including Paracetamol, Ibuprofen, Guaifenesin and Metformin. It exports nearly 60% of its revenue to the US and Europe. Its key customers include some of the leading generic, as well as, branded pharmaceutical companies. Its integrated model for manufacturing APIs, PFIs and Finished Dosages enables it to provide products across the value chain and enhances its competitiveness. It has emerged into a knowledge driven, R&D focused, multi-product organization, with inherent strength in efficient manufacturing of high-volume pharmaceutical products.

Business area of the company

Granules India is one of the vertically integrated, high-growth pharmaceutical manufacturing company in India today. Based out of Hyderabad, India, it is into manufacturing Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediaries (PFIs) and Finished Dosages (FDs).

Products of the company

  • Active Pharmaceutical Ingredients
  • Pharmaceutical Formulation Intermediates
  • Finished Dosages
  • Speciality Products

Milestones

  • 1991: Trading of APIs
  • 1994: Production of various APIs
  • 1995: Venture into the manufacture of DC Paracetemol (PFI)
  • 1996: Targeting of OTC market in the US for Paracetemol PFI.
  • 1998: Expansion of PFI capacity.
  • 2000: Obtaining US FDA approval for PFI and other APIs.
  • 2001: Development of new PFIs such as Guaifenesin, Metformin and Ibuprofen etc.
  • 2002: Filing of new DMFs of the above PFIs and moving up of value chain in OTC products.
  • 2003: Setting up of the world's single largest PFI facility with a capacity of 7,200 TPA.
  • 2004: The only company in the world to manufacture combination PFIs on a commercial scale using different basic APIs with other excipients.
  • 2004: Addition of a Tableting facility with a capacity of one billion pieces per annum
  • 2005: Started construction of the Tableting facility with a capacity of 12 billion tablets.
  • 2006: Major expansion of Paracetamol facility, from a capacity of 3600 MT to 12000MT per annum
  • 2010: Granuels India Receives U.S. FDA Approval for its Metformin ANDA.
  • 2011: Granules established Granules-OmniChem, a JV with Ajinomoto OmniChem. The business focuses on the CRAMS space
  • 2012: Granules India Awarded India’s Most Admired Company in Exports & India’s Most Admired Company in Bulk Drugs.
  • 2012: Granules India Awarded Outstanding Exports - Formulations Award 2011-12 by Pharmexcil.
  • 2013: Granules acquired Auctus Pharma.
  • 2016: Wholly owned subsidiary Granules Pharmaceticals Inc (GPI) enters into agreement to acquire 12.5% stake in US based USPharma.
  • 2017: Granules India Limited featured in the list at 60th place in Fortune India's 2017 list of The Next 500 Companies.
  • 2018-19: Granules Pharmaceuticals Inc. launched generic Methylergonovine tablets (Methergine) in partnership with Hikma Pharmaceuticals Plc.
  • 2018-19: Granules Pharmaceuticals Inc. successfully launched Metformin XR and Methocarbamol under its own label.
  • 2020: Granules India gets nod to set up subsidiary in Hyderabad.
  • 2020: Granules India gets marketing approval from US FDA for Potassium Chloride Extended Release Tablets.
  • 2021: USFDA approves ANDA filed by Granules India’s arm for Potassium Chloride Oral Solution.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×